Quadrant Capital Group LLC Neurocrine Biosciences Inc Transaction History

Quadrant Capital Group LLC

$1.43 Billion
Q4 2024

A detailed history of Quadrant Capital Group LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Quadrant Capital Group LLC holds 2,289 shares of NBIX stock, worth $268,225. This represents 0.02% of its overall portfolio holdings.

Number of Shares

2,289

Previous 2,312 0.99%

Holding current value

$268,225

Previous $266,000 17.29%

% of portfolio

0.02%

Previous 0.02%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	SELL	$111.62 - $139.44 $2,567 - $3,207	-23 Reduced 0.99%	2,289 $312,000
Q3 2024 Nov 12, 2024	SELL	$114.58 - $153.15 $5,270 - $7,044	-46 Reduced 1.95%	2,312 $266,000
Q2 2024 Aug 12, 2024	BUY	$130.86 - $143.19 $32,976 - $36,083	252 Added 11.97%	2,358 $324,000
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $4,042 - $4,455	31 Added 1.49%	2,106 $290,000
Q4 2023 Feb 08, 2024	BUY	$106.07 - $132.76 $8,273 - $10,355	78 Added 3.91%	2,075 $273,000
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $71,925 - $89,581	765 Added 62.09%	1,997 $224,000
Q2 2023 Aug 09, 2023	BUY	$89.53 - $104.87 $36,259 - $42,472	405 Added 48.97%	1,232 $116,000
Q1 2023 May 11, 2023	SELL	$94.11 - $123.02 $44,984 - $58,803	-478 Reduced 36.63%	827 $83,000
Q4 2022 Feb 10, 2023	BUY	$106.72 - $127.06 $39,166 - $46,631	367 Added 39.13%	1,305 $155,000
Q3 2022 Nov 10, 2022	BUY	$92.03 - $107.81 $55,310 - $64,793	601 Added 178.34%	938 $100,000
Q2 2022 Aug 09, 2022	SELL	$75.79 - $100.07 $4,395 - $5,804	-58 Reduced 14.68%	337 $33,000
Q1 2022 May 06, 2022	BUY	$72.45 - $94.81 $28,183 - $36,881	389 Added 6483.33%	395 $37,000
Q4 2021 Feb 01, 2022	SELL	$79.65 - $106.22 $14,655 - $19,544	-184 Reduced 96.84%	6 $1,000
Q3 2021 Nov 12, 2021	BUY	$86.18 - $99.03 $11,289 - $12,972	131 Added 222.03%	190 $18,000
Q2 2021 Aug 09, 2021	SELL	$89.43 - $102.27 $4,203 - $4,806	-47 Reduced 44.34%	59 $6,000
Q1 2021 May 12, 2021	BUY	$87.57 - $119.4 $2,014 - $2,746	23 Added 27.71%	106 $10,000
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $18,685 - $23,290	-215 Reduced 72.15%	83 $8,000
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $42,214 - $59,330	-439 Reduced 59.57%	298 $29,000
Q2 2020 Aug 13, 2020	BUY	$85.09 - $130.36 $2,722 - $4,171	32 Added 4.54%	737 $90,000
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $1,577 - $2,388	21 Added 3.07%	705 $61,000
Q2 2019 Jul 24, 2019	BUY	$72.24 - $91.27 $2,167 - $2,738	30 Added 4.59%	684 $56,000
Q1 2019 Apr 29, 2019	BUY	$69.31 - $91.53 $44,843 - $59,219	647 Added 9242.86%	654 $56,000
Q4 2018 Jan 17, 2019	SELL	$68.32 - $124.36 $4,714 - $8,580	-69 Reduced 90.79%	7 $0
Q4 2017 Jan 31, 2018	BUY	$58.53 - $77.59 $4,448 - $5,896	76	76 $5,000

Others Institutions Holding NBIX

# of Institutions

643

Shares Held

94.7M

Call Options Held

615K

Put Options Held

570K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.

Account

Quadrant Capital Group LLC Neurocrine Biosciences Inc Transaction History